Scientific KnowledgeLooking for development status?Clinical stage, comparable drugs/devices, and estimated availability are tracked in the Therapy Pipeline.
Bimokalner (ACOU085)
Kv7.4 potassium-channel opener (outer hair cells)
Evidence level
No primary evidence catalogued yet
How it works
A small molecule (Acousia) that opens Kv7.4 potassium channels in cochlear outer hair cells. This is a peripheral, hearing-protective target distinct from the central Kv7.2/3 channels of the Potassium Channel Dysfunction hypothesis: positive Phase 2a results (2026) are for preventing cisplatin-induced hearing loss, and the mechanism is untested for tinnitus. Included for completeness given the shared Kv7 channel family.
This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.
Explore connections· click any item to explore
Sponsor1